However, despite their initial promise in pre-clinical studies, overall efficacy of TRAIL agonists in a variety of cancer types has been limited to a minority of partial or complete responders culminating in a limited clinical uptake [10–18]. This evidence concerns the gene TNFSF10 and cancer.